Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | PEPD | P12955 | 2/20 | 0.46 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352620 | 1.00 | CMA1 (0.51) | CMA1CTSLCTSBCTSKKLK5 | |
| SCHEMBL8168154 | 1.00 | CMA1 (0.51) | CMA1CTSLCTSBCTSKKLK5 | |
| SCHEMBL12598149 | 0.90 | ELANE (0.48) | CMA1CTSLCTSBCTSKELANE | |
| SCHEMBL1985159 | 0.90 | ELANE (0.48) | CMA1CTSLCTSBCTSKELANE | |
| SCHEMBL28581548 | 0.90 | KLK5 (0.48) | CMA1CTSLCTSBCTSKKLK5 | |
| SCHEMBL28581545 | 0.90 | KLK5 (0.48) | CMA1CTSLCTSBCTSKKLK5 | |
| SCHEMBL2162326 | 0.89 | CMA1 (0.61) | CMA1CTSLCTSBCTSKELANE | |
| SCHEMBL13258959 | 0.89 | CMA1 (0.51) | CMA1CTSLCTSBCTSKELANE | |
| SCHEMBL8168155 | 0.89 | CMA1 (0.61) | CMA1CTSLCTSBCTSKELANE | |
| SCHEMBL4445986 | 0.89 | CMA1 (0.61) | CMA1CTSLCTSBCTSKELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115210244-B | Elastase inhibitor prodrug and application thereof | 苏州爱科百发生物医药技术有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118772216-A | 5-Fluorouracil nucleoside phosphoramidate compound and application thereof | 北京深蓝泰医药科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-115210244-A | Prodrug of elastase inhibitor and application thereof | 苏州爱科百发生物医药技术有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-113372368-B | Prodrug of elastase inhibitor and application thereof | 苏州爱科百发生物医药技术有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-113372368-A | Prodrug of elastase inhibitor and application thereof | 苏州爱科百发生物医药技术有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10400263-B2 | Tripeptide rhodamine compound | KINGSTON UNIVERSITY HIGHER EDUCATION CORPORATION (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-2875040-B1 | RHODAMINE BASED FLUORESCENT PROBE FOR COAGULASE ACTIVITY AND DETECTION OF COAGULASE PRODUCING BACTERIAL STRAINS | KINGSTON UNIV HIGHER EDUCATION CORP (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-20150240283-A1 | Compound | Kingston Universty Higher Education Corporation (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20150240283-A1 | Compound | Kingston Universty Higher Education Corporation (GB) | 2015-08-27 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
| US-4691007-A | HUMAN LEUKOCYTE ELASTASE INHIBITORS | ICI AMERICAS INC. (US) | 1987-09-01 | — | — | US | disclosed |
| US-4596789-A | Pharmaceuticals | ICI AMERICAS INC. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0124317-A2 | Proline derivatives | ICI AMERICAS INC. (US) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10400263-B2 | Tripeptide rhodamine compound | RNPEP, PEPD, DNPEP | CMA1 409/4885CTSL 13/4885CTSB 62/4885 |
| US-20150240283-A1 | Compound | RPIA, STS, CLPP | CMA1 247/4885CTSL 62/4885CTSB 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.